ARA-290

What is Ara-290?

Ara-290 is an investigational medication being studied to treat nerve damage (neuropathy) in people with diabetes or sarcoidosis. It is a synthetic peptide, which is a small protein-like molecule, designed to help protect and repair damaged nerves. Ara-290 is given as an injection under the skin, similar to how insulin is given. It is important to know that Ara-290 is not yet approved by the FDA and is only available through clinical research studies.

How Does It Work?

Ara-290 works by activating your body's natural repair systems. It attaches to special receptors on cells that trigger healing and reduce inflammation. Unlike some similar medications that affect red blood cell production, Ara-290 specifically targets tissue protection and repair without affecting your blood counts. The medication helps protect nerve fibers from further damage, reduces pain signals, and may help damaged nerves heal over time. It also reduces inflammation that contributes to nerve damage in conditions like diabetes and sarcoidosis.

How Do You Take It?

If you are participating in a research study with Ara-290, you will receive it as a daily injection under your skin. Your healthcare team will teach you how to give yourself these injections, or they may give them to you at the clinic. The injection can be given in your abdomen, thigh, or upper arm, and you should rotate where you inject to avoid irritation. Most studies use doses between 1 and 8 mg once daily, depending on your condition. Treatment typically lasts for several weeks to months. It is important to follow your study schedule carefully and not miss doses. Store the medication in your refrigerator and protect it from light.

What Are Common Side Effects?

Most people tolerate Ara-290 well, but like all medications, it can cause side effects. The most common side effect is irritation where you inject the medication, including redness, pain, or swelling. These reactions are usually mild and go away on their own. Other common side effects include headaches, feeling tired, mild nausea, and dizziness. These effects are typically not serious and often improve as your body adjusts to the medication. If you experience severe pain, swelling, or signs of infection at the injection site, contact your healthcare provider. You should also call your doctor if you develop severe headaches, chest pain, difficulty breathing, or signs of an allergic reaction such as rash, itching, or swelling of your face or throat. Because this is an investigational medication, your healthcare team will monitor you closely throughout the study for any unexpected effects.

Ara-290 (also known as ARA 290 or cibinetide) is a synthetic peptide compound developed as a selective agonist of the innate repair receptor. The compound was designed based on the tissue-protective domain of erythropoietin (EPO), specifically engineered to retain the cytoprotective and anti-inflammatory properties of EPO while eliminating its erythropoietic activity. This selective activity profile was achieved by identifying and synthesizing the minimal peptide sequence necessary for tissue protection, resulting in an 11-amino acid peptide that represents a non-erythropoietic EPO derivative.

The development of Ara-290 emerged from research into the pleiotropic effects of erythropoietin, which demonstrated tissue-protective properties beyond red blood cell production. While full-length EPO showed promise in treating various tissue injury conditions, its erythropoietic effects posed significant safety concerns, including increased risk of thrombotic events, hypertension, and tumor progression. Ara-290 was developed by Araim Pharmaceuticals (later acquired by Araim Pharmaceuticals) to harness the beneficial tissue-protective effects while avoiding these hematologic complications. The compound has been investigated in multiple clinical trials since the early 2010s.

Ara-290 is currently an investigational compound without FDA approval or approval from other major regulatory agencies. Clinical development has focused primarily on neuropathic conditions, including diabetic peripheral neuropathy, sarcoidosis-associated small fiber neuropathy, and diabetic macular edema. The compound has also been studied in type 2 diabetes and prediabetes for its potential metabolic effects. Clinical trials have been conducted in the United States, Europe, and other regions, with various phase 2 studies evaluating safety, tolerability, and preliminary efficacy.

The therapeutic rationale for Ara-290 centers on its ability to activate innate repair mechanisms and reduce pathological inflammation without stimulating red blood cell production. In neuropathic conditions, the compound aims to protect existing nerve fibers from further damage, reduce neuropathic pain, and potentially promote nerve regeneration. The subcutaneous route of administration used in clinical trials allows for convenient outpatient treatment. Despite promising preclinical and early clinical data, the compound has not yet advanced to late-stage pivotal trials or regulatory approval.

The significance of Ara-290 in current medical research lies in its novel mechanism of selectively activating tissue-protective pathways. If successfully developed, it could represent a new therapeutic class for treating neuropathic conditions and other diseases characterized by tissue injury and inflammation. The compound's development has also contributed to broader understanding of the innate repair receptor and its role in tissue homeostasis and repair.

Ara-290 is an 11-amino acid peptide that functions as a selective agonist of the innate repair receptor (IRR), also known as the tissue-protective receptor. This receptor is a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (βcR or CD131). Unlike full-length erythropoietin, Ara-290 selectively activates the tissue-protective pathway without stimulating erythropoiesis, thereby avoiding the hematologic effects associated with traditional EPO therapy.

Upon binding to the innate repair receptor, Ara-290 initiates intracellular signaling cascades that promote cytoprotection, reduce inflammation, and facilitate tissue repair. The primary signaling pathways activated include the JAK2/STAT3, PI3K/Akt, and MAPK pathways. These cascades lead to anti-apoptotic effects, reduction of oxidative stress, and modulation of inflammatory cytokine production. The compound has demonstrated particular efficacy in protecting small nerve fibers from damage and promoting their regeneration.

In neuropathic conditions, Ara-290's mechanism involves reducing neuroinflammation, protecting nerve cells from metabolic and oxidative injury, and promoting nerve fiber regeneration. The compound has been shown to reduce levels of pro-inflammatory cytokines such as TNF-α and IL-6 while enhancing anti-inflammatory mediators. Additionally, Ara-290 appears to improve microvascular function and reduce endothelial dysfunction, which may contribute to its therapeutic effects in diabetic complications.

The tissue-protective effects of Ara-290 extend beyond the nervous system, with potential applications in protecting various tissues from ischemic, inflammatory, and metabolic injury. The compound's ability to separate tissue protection from erythropoietic effects represents a significant advancement in the therapeutic application of EPO-related biology.

General Dosing Principles

Ara-290 is administered via subcutaneous injection. As an investigational compound without regulatory approval, the following dosing information is derived from clinical trial protocols and should not be considered standard clinical practice guidelines. All dosing should occur under appropriate research protocols or investigational frameworks with proper oversight and informed consent.

Dosing by Indication

Sarcoidosis-Associated Small Fiber Neuropathy

Titration Schedule:

• Week 1-4: 1-8 mg administered subcutaneously daily for 28 consecutive days

• Dosing typically initiated at lower end of range with potential escalation based on tolerability

Alternative Regimen:

• 2 mg three times daily (TID) has been studied in some sarcoidosis protocols

Diabetic Peripheral Neuropathy and Type 2 Diabetes

This dosing regimen applies to:

• Type 2 diabetes with neuropathic symptoms

• Prediabetes with early neuropathic changes

• Diabetic peripheral neuropathy

Diabetic Macular Edema

Administration Instructions

Preparation:

• Ara-290 is supplied as a lyophilized powder requiring reconstitution or as a pre-filled syringe (formulation varies by study)

• If reconstitution required, use appropriate sterile diluent as specified in study protocol

• Gently swirl to dissolve; do not shake vigorously

• Inspect solution for particulate matter and discoloration before administration

Injection Technique:

• Administer via subcutaneous injection in abdomen, thigh, or upper arm

• Rotate injection sites to minimize local reactions

• Use proper aseptic technique

• Patients may be trained for self-administration in outpatient settings

Special Populations

Renal Impairment

No specific dose adjustments have been established in clinical trials. Given peptide metabolism and renal elimination, caution may be warranted in severe renal impairment, though formal studies are lacking.

Hepatic Impairment

No specific dose adjustments established. Hepatic metabolism is not a primary elimination pathway for this peptide compound.

Geriatric Patients

No specific dose adjustments recommended based on age alone. Many clinical trial participants have been older adults with diabetes or sarcoidosis.

Pediatric Patients

Safety and efficacy have not been established in pediatric populations. No pediatric dosing guidelines available.

Pregnancy and Lactation

No human data available. Use only if potential benefit justifies potential risk in investigational settings.

Missed Doses

In clinical trial settings, if a dose is missed, it should typically be administered as soon as remembered on the same day, with the regular schedule resumed the following day. Patients should not double doses to make up for missed administrations.

Storage and Handling

• Store lyophilized powder refrigerated at 2-8°C (36-46°F)

• Protect from light

• Once reconstituted, use immediately or store as directed by specific formulation guidelines

• Do not freeze

• Keep out of reach of children

Clinical development of Ara-290 has encompassed multiple phase 2 trials evaluating its efficacy and safety in various neuropathic conditions. The most extensively studied indication has been sarcoidosis-associated small fiber neuropathy, a painful condition characterized by damage to small nerve fibers. A randomized, double-blind, placebo-controlled trial investigated Ara-290 in patients with sarcoidosis-associated small nerve fiber loss and damage (SNFLD). This study employed doses ranging from 1-8 mg administered subcutaneously daily for 28 consecutive days. Results demonstrated improvements in neuropathic pain scores and quality of life measures, with some patients showing increases in intraepidermal nerve fiber density, an objective measure of small fiber regeneration.

In diabetic neuropathy, clinical trials have evaluated Ara-290 in patients with type 2 diabetes experiencing neuropathic symptoms. A phase 2 study administered 4 mg daily subcutaneously to assess effects on neuropathic pain, sensory function, and nerve fiber density. Preliminary results suggested improvements in patient-reported pain scores and some objective measures of nerve function, though the magnitude of benefit varied among participants. Additional studies have explored Ara-290 in patients with prediabetes and early type 2 diabetes, investigating potential disease-modifying effects on metabolic parameters and early neuropathic changes. These studies utilized similar dosing regimens of 4 mg daily administered subcutaneously.

Diabetic macular edema has also been investigated as a potential indication for Ara-290, based on the compound's anti-inflammatory and tissue-protective properties. A clinical trial evaluated 4 mg daily dosing in patients with diabetic macular edema, assessing effects on retinal thickness, visual acuity, and inflammatory biomarkers. The rationale for this indication stems from the role of inflammation and microvascular dysfunction in diabetic retinopathy. Some studies have employed alternative dosing regimens, including 2 mg administered three times daily (TID) in sarcoidosis patients, exploring whether more frequent dosing might enhance therapeutic effects.

Safety and tolerability data from clinical trials have generally been favorable, with Ara-290 demonstrating an acceptable safety profile across studied doses and indications. The most commonly reported adverse events have been mild injection site reactions, consistent with subcutaneous peptide administration. Importantly, no significant erythropoietic effects or increases in hemoglobin/hematocrit have been observed, confirming the selective tissue-protective activity without hematologic stimulation. Single-dose studies in healthy volunteers established initial safety parameters and pharmacokinetic profiles that informed subsequent patient studies.

Despite promising early clinical signals, Ara-290 has not yet advanced to phase 3 pivotal trials or regulatory approval. The clinical development program has faced challenges common to neuropathy drug development, including heterogeneity in patient populations, variability in outcome measures, and the chronic progressive nature of these conditions. Additional studies may be needed to identify optimal patient populations, refine dosing strategies, and establish clinically meaningful endpoints. The extracted clinical trial data indicates ongoing research interest in multiple indications, though the current regulatory and commercial status of the compound remains investigational.

Contraindications

As an investigational compound, formal contraindications have not been established through regulatory approval processes. However, based on clinical trial exclusion criteria and theoretical considerations, the following would represent contraindications or preclusions to use:

Absolute Contraindications:

• Known hypersensitivity to Ara-290 or any component of the formulation

• Known hypersensitivity to erythropoietin or erythropoiesis-stimulating agents

• Active malignancy or history of malignancy within specified timeframes (typically 5 years in clinical trials)

• Uncontrolled hypertension

• History of thromboembolic events in certain timeframes

Relative Contraindications:

• Severe renal impairment (use with caution; limited data available)

• Pregnancy and lactation (insufficient safety data)

• Concurrent use of other investigational agents

• Significant cardiovascular disease depending on trial protocols

Adverse Effects

Common Adverse Effects (>5% incidence)

Based on clinical trial safety data, the most frequently reported adverse effects include:

• Injection site reactions: Pain, erythema, swelling, bruising at injection site (most common adverse effect)

• Headache: Mild to moderate intensity, typically transient

• Fatigue: Generally mild and self-limiting

• Nausea: Occasional gastrointestinal discomfort

• Dizziness: Typically mild and not dose-limiting

These common adverse effects are generally mild in severity and do not require treatment discontinuation in most cases.

Serious Adverse Effects

Serious adverse events have been infrequent in clinical trials. Potential serious adverse effects requiring monitoring include:

• Hypersensitivity reactions: Although rare, allergic reactions including anaphylaxis are theoretically possible with peptide therapeutics

• Cardiovascular events: While Ara-290 lacks erythropoietic activity, monitoring for cardiovascular events has been standard in trials given the EPO-related mechanism

• Thromboembolic events: Theoretical concern based on EPO biology, though not observed at increased rates in clinical trials

• Infection: Immunomodulatory effects warrant monitoring for infections

Warnings and Precautions

Hematologic Monitoring: Although Ara-290 is designed to lack erythropoietic activity, periodic monitoring of hemoglobin, hematocrit, and complete blood counts has been standard practice in clinical trials to confirm absence of erythropoietic effects.

Cardiovascular Monitoring: Blood pressure monitoring is recommended, particularly in patients with pre-existing hypertension or cardiovascular disease. While the compound lacks the erythropoietic effects associated with cardiovascular risks of full-length EPO, vigilance remains appropriate.

Injection Site Care: Patients should be educated on proper injection technique, site rotation, and recognition of injection site infections. Persistent or worsening injection site reactions should be evaluated.

Immunogenicity: As with all peptide therapeutics, there is potential for development of anti-drug antibodies. Clinical trials have included monitoring for immunogenicity, though significant antibody formation has not been a major concern in published data.

Special Populations

Pregnancy (Category Not Assigned)

Ara-290 has not been studied in pregnant women. Animal reproductive studies may be limited or unavailable. Use only in investigational settings where potential benefits justify potential risks, with appropriate informed consent and oversight.

Lactation

It is unknown whether Ara-290 is excreted in human milk. Given the peptide nature, oral absorption by nursing infants would likely be minimal, but data are lacking. Decisions regarding breastfeeding during investigational use should consider potential infant exposure and benefits of breastfeeding.

Pediatric Use

Safety and efficacy have not been established in pediatric populations. Clinical trials have focused on adult patients.

Geriatric Use

Many clinical trial participants have been older adults with diabetes or sarcoidosis. No specific age-related safety concerns have been identified, though older patients may have multiple comorbidities requiring careful monitoring.

Renal Impairment

Formal studies in renal impairment have not been conducted. Given peptide elimination pathways, severe renal impairment may affect clearance, though clinical significance is unclear.

Hepatic Impairment

No specific precautions established. Hepatic metabolism is not a primary elimination pathway.

Monitoring Parameters

In clinical trial settings, the following monitoring has been standard:

• Baseline and periodic complete blood counts (hemoglobin, hematocrit, platelets, white blood cells)

• Blood pressure monitoring at each visit

• Injection site assessment at each administration

• Vital signs including heart rate and temperature

• Adverse event monitoring through patient reporting and clinical assessment

• Disease-specific measures (e.g., neuropathy pain scores, nerve fiber density assessments)

• Metabolic parameters in diabetes studies (glucose, HbA1c)

• Renal function (serum creatinine, estimated GFR)

• Hepatic function (liver enzymes) at baseline and periodically

Overdose

No cases of overdose have been reported in clinical trials. Given the peptide nature and mechanism of action, acute toxicity from overdose is expected to be low. Management would be supportive and symptomatic. There is no specific antidote for Ara-290 overdose.

Pharmacokinetics

The pharmacokinetic profile of Ara-290 has been characterized through clinical studies involving subcutaneous administration. Following subcutaneous injection, Ara-290 demonstrates relatively rapid absorption with peak plasma concentrations typically achieved within 1-3 hours post-administration. The compound exhibits dose-proportional pharmacokinetics across the studied dose range of 1-8 mg. As a peptide compound, Ara-290 has limited oral bioavailability due to degradation by gastrointestinal proteases, necessitating parenteral administration for therapeutic use.

The distribution of Ara-290 appears to be primarily extracellular, consistent with its peptide nature and molecular weight. The volume of distribution suggests limited tissue penetration, though the compound reaches therapeutic targets including peripheral nerves and microvascular endothelium. Protein binding data for Ara-290 has not been extensively published, though peptides of this size typically exhibit moderate to high plasma protein binding. The elimination half-life of Ara-290 is relatively short, estimated at 2-4 hours, which influences the dosing frequency required to maintain therapeutic concentrations.

Metabolism of Ara-290 occurs primarily through proteolytic degradation by peptidases and proteases throughout the body, consistent with the metabolic fate of other therapeutic peptides. The compound does not undergo hepatic cytochrome P450-mediated metabolism, which reduces the potential for drug-drug interactions with medications metabolized by these enzymes. Elimination occurs primarily through renal filtration and proteolytic degradation, with metabolites excreted in urine. The short half-life and peptide nature of the compound result in minimal accumulation with repeated dosing.

Pharmacodynamics

The pharmacodynamic effects of Ara-290 are mediated through activation of the innate repair receptor, leading to downstream cellular responses that manifest over hours to days. Biomarker studies have demonstrated that Ara-290 treatment reduces circulating levels of inflammatory markers including C-reactive protein (CRP) and pro-inflammatory cytokines. In patients with neuropathy, treatment has been associated with improvements in corneal nerve fiber density and intraepidermal nerve fiber density, objective measures of small fiber nerve health that correlate with clinical symptoms.

Dose-response relationships have been evaluated in clinical trials, with doses ranging from 1 mg to 8 mg administered subcutaneously. Studies in sarcoidosis-associated neuropathy utilized doses up to 8 mg daily, while diabetic neuropathy studies employed 4 mg daily dosing. The pharmacodynamic effects appear to be sustained with continued treatment, and some studies suggest that benefits may persist for a period after treatment discontinuation, consistent with tissue repair and regeneration mechanisms.

Drug Interactions

Given its peptide nature and mechanism of action, Ara-290 has a relatively low potential for pharmacokinetic drug-drug interactions. The compound does not inhibit or induce cytochrome P450 enzymes, reducing concerns about interactions with medications metabolized through these pathways. No significant pharmacokinetic interactions have been reported with common medications used in diabetic or sarcoidosis patients, including metformin, insulin, corticosteroids, or immunosuppressive agents. However, comprehensive interaction studies have not been conducted for all potential co-medications. Theoretical concerns exist regarding concurrent use with other agents affecting tissue repair or inflammatory pathways, though clinical significance remains unclear.